[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].

@article{Team2020TheEC,
  title={[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].},
  author={Novel Coronavirus Pneumonia Emergency Response Epidemiol Team},
  journal={Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi},
  year={2020},
  volume={41 2},
  pages={
          145-151
        }
}
  • Novel Coronavirus Pneumonia Emergency Response Epidemiol Team
  • Published 2020
  • Medicine
  • Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • Objective: An outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. Here, we report results of a descriptive, exploratory analysis of all cases diagnosed as of February 11, 2020. Methods: All COVID-19 cases reported through February 11, 2020 were extracted from China's Infectious Disease Information System. Analyses included: 1) summary of patient characteristics; 2) examination of age distributions and sex ratios; 3) calculation of case fatality… CONTINUE READING

    Paper Mentions

    OBSERVATIONAL CLINICAL TRIAL
    It has been demonstrated that respiratory virus outbreaks and pandemics, such as influenza, SARS, MERS, and now the newly emerged SARS-CoV-2 virus, have a major impact on morbidity and… Expand
    ConditionsCOVID-19
    INTERVENTIONAL CLINICAL TRIAL
    COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary… Expand
    ConditionsCOPD, Coronavirus Infection, Idiopathic Pulmonary Fibrosis, (+3 more)
    InterventionDevice, Drug, Procedure
    OBSERVATIONAL CLINICAL TRIAL
    This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication… Expand
    ConditionsAdverse Drug Event, COVID, Drug Effect, (+1 more)
    InterventionOther
    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.  
    ConditionsARDS, Human, COVID
    InterventionDrug

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 721 CITATIONS, ESTIMATED 79% COVERAGE

    FILTER CITATIONS BY YEAR

    2019
    2020

    CITATION STATISTICS

    • 26 Highly Influenced Citations

    • Averaged 360 Citations per year from 2019 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 10 REFERENCES

    Categories: Awaiting classification; Case study/case series Year: 2020 Author: Zhang, Wei; Du

    Categories: Case study/case series; Clinical care and treatment; Infection prevention and control Year: Author: The Lancet Infectious, Diseases Title: Challenges of coronavirus disease

    • The Lancet Infectious Diseases
    • 2019

    Categories: Case study/case series; Infection prevention and control

    • Virology, immunology

    Categories: Clinical care and treatment; Infection prevention and control; Narrative review Year: 2020 Author: Salata, Cristiano; Calistri, Arianna

    • Coronaviruses: a paradigm of new emerging zoonotic diseases Journal: Pathogens and Disease

    Categories: Ethics, social science, economics; Opinion piece Year: 2020 Author: Tian

    wards were the most important measures

    • JO -Intensive Care Medicine URL